We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 336

Janssen awarded damages almost 10 years after Teva found to have infringed LEVAQUIN patent
  • Gowling WLG
  • Canada
  • June 24 2016

In a recent decision of the Federal Court (Janssen Inc. v. Teva Canada Limited, 2016 FC 593), Justice Hughes awarded approximately $18 million in


Obviousness central to Federal Court’s REYATAZ (atazanavir bisulfate) decision
  • Gowling WLG
  • Canada
  • June 24 2016

In a decision dated May 27, 2016 in respect of Bristol-Myers Squibb’s (“BMS”) REYATAZ (atazanavir bisulfate), Justice Mactavish of the Federal


Post Amazon.com: How the Canadian Patent Appeal Board has dealt with patent-eligibility of computer-implemented subject matter
  • Gowling WLG
  • Canada
  • June 15 2016

Originally published on June 1, 2015 Updated on June 15, 2016 An important consideration for every patentee is that each countries’ patent system has


Applications for leave to appeal dismissed - 10 June 2016
  • Gowling WLG
  • Canada
  • June 10 2016

The applicant sought reconsideration of a decision of the Public Service Labour Relations and Employment Board (“Board”) dated February 21, 2008. She


Federal Court of Appeal affirms application of principles of causation, burden of proof and laws of evidence to section 8 proceedings
  • Gowling WLG
  • Canada
  • June 6 2016

In its recent decision, reported as Pfizer Canada Inc. v Teva Canada Limited, 2016 FCA 161, the Federal Court of Appeal ("FCA") overturned the


Federal Court releases updated guidelines to govern proceedings under the PM(NOC) Regulations
  • Gowling WLG
  • Canada
  • May 25 2016

Chief Justice Crampton of the Federal Court has released a notice to parties and the profession (the “Notice”) that sets out the standard procedure


Patent owner’s entitlement to permanent injunction confirmed
  • Gowling WLG
  • Canada
  • May 11 2016

In Uponor AB v Heatlink Group Inc (2016 FC 320) the Federal Court of Canada awarded a permanent injunction after a finding that the asserted patent


Eli Lilly’s Cialis patent withstands double patenting and utility challenges on appeal
  • Gowling WLG
  • Canada
  • April 26 2016

The Federal Court of Appeal has provided guidance on the law of obviousness-type double patenting in dismissing Mylan’s appeal pertaining to Eli


Patent owner’s entitlement to permanent injunction in Canada confirmed
  • Gowling WLG
  • Canada
  • April 21 2016

In Uponor AB v. Heatlink Group Inc. et al., 2016 FC 320 ("Uponor"), the Federal Court of Canada awarded a permanent injunction after a finding that


Competition Bureau releases guidelines in respect of settlements under the PM(NOC) Regulations
  • Gowling WLG
  • Canada
  • April 8 2016

On March 31, 2016, the Competition Bureau released its updated Intellectual Property Enforcement Guidelines (the "IPEGs"). The updated IPEGs replace